A Study of Rituximab in Frontline Therapy for Glomerulonephritis

Inclusion Criteria: * Primary MN, MCD/FSGS patients confirmed by biopsy * Consistent with nephrotic syndrome ( urinary protein\>3.5g/d and serum albumin\< 30g/L), and the researchers consider that immunosuppressive therapy is needed * Estimated glomerular filtration rate ( eGFR≥60 ml/min/1.73m2 ) * Patients providing written informed consent before initiation of any study-related activities Exclusion Criteria: * Previous treatment of rituximab * active bacteria, fungi, tuberculosis, viral infection * Secondary MN, MCD, FSGS ( such as active hepatitis, systemic lupus erythematosus, drugs, malignant tumors, genetic or diabetic nephropathy, etc. ) * Severe cardiac insufficiency, cardiac function in NYHA grade III above * Severe hypertension ( blood pressure\>180/110 mmHg ) that cannot be controlled by drug treatment * Pregnant or lactating female patients * Uncontrolled concurrent diseases, including but not limited to： 1. HIV infected ( HIV antibody positive ) 2. HBV or HCV infection 3. Evidence of severe or uncontrolled systemic diseases ( such as severe mental, neurological, epilepsy or dementia ) * Those currently undergoing clinical trials of other drugs * Other patients considered unsuitable for inclusion by the researchers